Abrham Mulugeta Shares Insights on Tranexamic Acid: Exploring the WHO WOMAN Trial
Abrham Mulugeta, Gynecologist at Tercha General Hospital, shared on LinkedIn:
”Drug review Tranexamic Acid (TXA)
Tranexamic Acid (TXA): Life-Saving Antifibrinolytic in Postpartum Hemorrhage (PPH)
TXA is a synthetic lysine analogue that inhibits fibrinolysis — stabilizing blood clots when every minute counts.
Mechanism:
Inhibits plasminogen activation → prevents fibrin degradation → promotes stable clot formation.
Dose (as per WHO and WOMAN trial):
1 g IV over 10 min, ideally within 3 hours of birth.
Repeat once after 30 min if bleeding continues or restarts.
Indicated for:
Treatment of postpartum hemorrhage (PPH) after vaginal or cesarean delivery.
Other indications according to local guidlines.
Evidence:
WOMAN Trial (Lancet 2017)
> 20 000+ women
→ Early TXA (≤3 h) ↓ maternal death due to bleeding by ~30 %.
Side effects:
Nausea, vomiting, dizziness
Rare: thromboembolic events → use cautiously in patients with active thrombosis
Key akeaway:
TXA reduces maternal mortality when given early alongside standard PPH management (uterotonics, IV fluids, surgical measures).
Timing matters — “The sooner, the stronger the benefit.”’
Stay updated with Hemostasis Today.
-
Aug 23, 2026, 17:51Gurpreet Kaurr: A Proud Milestone in Haematology and Oncology
-
Aug 23, 2026, 17:33Kathrine Kaspersen: How Voluntary Plasma Donors Helped Transform Denmark’s Plasma Supply
-
Aug 23, 2026, 16:51Sthanu Subramanian: Empagliflozin and a Rise in Hematocrit
-
Aug 23, 2026, 16:50Lale Tokgözoğlu: New PCSK9i Research Published in the European Heart Journal
-
Aug 23, 2026, 16:44Eric Gehrie: Your 2026 Guide to the Essentials of Transfusion Medicine
-
Aug 23, 2026, 16:35Thomas Dayspring: The Overlooked Pathway in Cholesterol Homeostasis
-
Aug 23, 2026, 16:28Evan Mapelu: The People Who Make Cancer Care Meaningful
-
Aug 23, 2026, 16:09Felice Gragnano: New Publication on Aspirin Discontinuation After PCI for Acute Coronary Syndromes
-
Aug 23, 2026, 16:06Mostafa Faisal: Donor Type and Long-Term Quality of Life After HCT for Severe Aplastic Anemia